These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 9055136

  • 21. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD.
    J Am Coll Cardiol; 2013 Feb 26; 61(8):872-9. PubMed ID: 23333143
    [Abstract] [Full Text] [Related]

  • 22. Interleukin-10 does not modulate clopidogrel platelet response in mice.
    Yin Q, Tai T, Ji JZ, Mi QY, Zhang MR, Huang WJ, Cao CC, Xie HG.
    J Thromb Haemost; 2016 Mar 26; 14(3):596-605. PubMed ID: 26712119
    [Abstract] [Full Text] [Related]

  • 23. Inhibitory effects of ticlopidine on platelet function as assessed by three different methods.
    Cuyun-Lira O, Kaneko M, Takafuta T, Satoh K, Ohnishi M, Yatomi Y, Ozaki Y.
    Eur J Pharm Sci; 2007 Jan 26; 30(1):21-5. PubMed ID: 17070023
    [Abstract] [Full Text] [Related]

  • 24. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
    Kobayashi M, Kajiwara M, Hasegawa S.
    J Atheroscler Thromb; 2015 Jan 26; 22(11):1186-96. PubMed ID: 26063503
    [Abstract] [Full Text] [Related]

  • 25. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD, Kang W, Lee HW, Park DJ, Ahn JH, Kim MJ, Kim EY, Kim SW, Nam HS, Na HJ, Yoon YR.
    Clin Ther; 2009 Apr 26; 31(4):793-803. PubMed ID: 19446152
    [Abstract] [Full Text] [Related]

  • 26. The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine.
    Farrell TP, Hayes KB, Sobel BE, Schneider DJ.
    Am J Cardiol; 1999 Mar 01; 83(5):770-4. PubMed ID: 10080435
    [Abstract] [Full Text] [Related]

  • 27. Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.
    Hurbin F, Boulenc X, Daskalakis N, Farenc C, Taylor T, Bonneau D, Lacreta F, Cheng S, Sultan E.
    J Clin Pharmacol; 2012 Oct 01; 52(10):1506-15. PubMed ID: 22128201
    [Abstract] [Full Text] [Related]

  • 28. Effect of ticlopidine on exercise-induced platelet aggregation and exercise tolerance time in patients with ischemic heart disease.
    Tsuruta M, Utsunomiya T, Yoshida K, Ogata T, Tsuji S, Tokushima T, Higuchi H, Matsuo S.
    J Cardiovasc Pharmacol; 1999 Apr 01; 33(4):659-64. PubMed ID: 10218739
    [Abstract] [Full Text] [Related]

  • 29. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis.
    Denninger MH, Necciari J, Serre-Lacroix E, Sissmann J.
    Semin Thromb Hemost; 1999 Apr 01; 25 Suppl 2():41-5. PubMed ID: 10440422
    [Abstract] [Full Text] [Related]

  • 30. [Effects of ticlopidine on platelet function at rest and after exercise in patients with previous myocardial infarct. An acute crossover double-blind study].
    Tullio D, Valerio A, Ottaviano MA, Di Guglielmo L, Accettura P, Caraceni CE, Sclocco T.
    Minerva Med; 1990 Apr 01; 81(1-2):87-92. PubMed ID: 2179769
    [Abstract] [Full Text] [Related]

  • 31. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
    Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G.
    Eur Heart J; 2006 May 01; 27(9):1038-47. PubMed ID: 16476694
    [Abstract] [Full Text] [Related]

  • 32. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
    Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M.
    Clin Pharmacol Ther; 2011 Jan 01; 89(1):65-74. PubMed ID: 20844485
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin.
    Wittke B, Ensor H, Chung J, Birnböck H, Lausecker B, Ertel SI, MacKie IJ, Machin SJ.
    Br J Clin Pharmacol; 2000 Mar 01; 49(3):231-9. PubMed ID: 10718778
    [Abstract] [Full Text] [Related]

  • 34. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
    Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, Ernest CS, Salazar DE, Konkoy CS, Winters KJ.
    Pharmacotherapy; 2008 Dec 01; 28(12):1483-94. PubMed ID: 19025429
    [Abstract] [Full Text] [Related]

  • 35. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
    Pedersen RS, Nielsen F, Stage TB, Vinholt PJ, el Achwah AB, Damkier P, Brosen K.
    Clin Exp Pharmacol Physiol; 2014 Nov 01; 41(11):870-8. PubMed ID: 25115434
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics of ticlopidine in the rabbit.
    Onyeji CO, Tessier PR, Nightingale CH, Vallee F, Nicolau DP.
    J Pharm Pharmacol; 1999 Apr 01; 51(4):393-6. PubMed ID: 10385210
    [Abstract] [Full Text] [Related]

  • 37. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
    Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS, Brandt JT, Darstein C, Jakubowski JA, Salazar DE.
    Clin Pharmacol Ther; 2007 May 01; 81(5):735-41. PubMed ID: 17361128
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients.
    Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F.
    J Am Coll Cardiol; 2004 Mar 17; 43(6):979-84. PubMed ID: 15028353
    [Abstract] [Full Text] [Related]

  • 39. Enhancement of platelet inhibition of ticlopidine plus aspirin vs aspirin alone given prior to elective PTCA.
    van de Loo A, Nauck M, Noory E, Just H, Wollschläger H.
    Eur Heart J; 1998 Jan 17; 19(1):96-102. PubMed ID: 9503181
    [Abstract] [Full Text] [Related]

  • 40. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
    Umemura K, Kondo K, Ikeda Y, Nakashima M.
    Thromb Haemost; 1997 Nov 17; 78(5):1381-4. PubMed ID: 9408023
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.